Acquiring Company
AstraZeneca Plc
Acquired Company
Rhythm Pharmaceuticals
Cambridge
BostonBiotechnologyHealth CarePharmaceuticalBiopharmaBiotechnologyHealthcareHealth CareTherapeuticsDescription
AstraZeneca has proposed acquiring Rhythm Pharmaceuticals in a deal valued at approximately $10 billion. The headline describes the offer as a proposal, so the transaction is not yet agreed or completed.
Who to call at AstraZeneca Plc, and when
When AstraZeneca Plc changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day AstraZeneca Plc raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at AstraZeneca Plc, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at AstraZeneca Plc. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment AstraZeneca Plc makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals was acquired by AstraZeneca Plc, based in Cambridge. The deal was reported on November 8, 2026. AstraZeneca is a global, science-led biopharmaceutical company. It focuses on the discovery, development, and commercialization of prescription medicines. AstraZeneca Plc is publicly traded (AZN) and operates in Biotechnology.
When did AstraZeneca Plc acquire Rhythm Pharmaceuticals?
AstraZeneca Plc's acquisition of Rhythm Pharmaceuticals was reported on November 8, 2026. AstraZeneca has proposed acquiring Rhythm Pharmaceuticals in a deal valued at approximately $10 billion. The headline describes the offer as a proposal, so the transaction is not yet agreed or completed. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Rhythm Pharmaceuticals do?
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases. It is publicly traded (RYTM), operating in Biotechnology, and is based in Boston.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.